

Molecular Therapeutics of Cancer Research Conference -- 2014

Sponsored by the Cancer Molecular Therapeutics Research Association

Schedule and Program

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.

NOTE: ALL SCIENTIFIC SESSIONS, POSTERS AND SOCIALS WILL BE HELD IN THE CHAPEL.

Lodging will be throughout the Asilomar campus. All meals will be served in the Crocker Dining Hall

SUNDAY – JULY 13

4:00 pm	Arrival and check-in
6:00 – 7:00 pm	<i>Dinner</i>
7:30 – 7:45 pm	Welcome / Introductory Comments Peter Houghton, Nationwide Children’s Hospital, Columbus, OH, President CMTRA Jeff Settleman, Genentech, San Francisco, CA, Program Chair
7:45 – 10:00 pm	EVENING SESSION: “Prostate Cancer” Discussion Leader: Chuck Ryan, University of California, San Francisco
7:45 – 8:00 pm	Introduction
8:00 – 8:30 pm	Andy Protter, Medivation, San Francisco, CA “Androgen Receptor Signaling and Prostate Cancer and Development of a Novel Therapeutic”
8:30 – 8:55 pm	Discussion
9:00 – 9:30 pm	Lawrence Fong, University of California, San Francisco “Immune Recognition of Prostate Cancer”
9:35 – 10:00 pm	Discussion
10:00 pm –	<i>Social</i>

MONDAY – JULY 14

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	MORNING SESSION: – “Targeting Tumor Metabolism—Opportunity vs Plasticity” Discussion Leader: Matt van der Heiden, Massachusetts Institute of Technology, Cambridge, MA
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	David Schenkein, Agios, Cambridge, MA “IDH and Cancer”

9:15 – 9:40 am	Discussion
9:40 – 10:00 am	<i>Coffee Break</i>
10:00 – 10:30 am	Nika Danial, Dana Farber Cancer Institute, Boston, MA “Metabolic Heterogeneity in Molecular Subtypes of Diffuse Large B Cell Lymphoma”
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	Navdeep S. Chandel, Northwestern University, Evanston, IL “Targeting Mitochondria for Cancer Therapy”
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
2:00 – 4:10 pm	AFTERNOON SESSION: “Tumor Heterogeneity and Cancer Stem Cells” Discussion Leader: Helen Blau, Stanford University, Stanford, CA
2:00 – 2:15 pm	Introduction
2:15 – 2:45 pm	Nelly Polyak, Dana Farber Cancer Institute, Boston, MA “Breast Tumor Evolution”
2:45 – 3:10 pm	Discussion
3:15 – 3:45 pm	Adina Vultur, Wistar Institute, Philadelphia, PA “Targeting Subpopulations of Melanoma Cells”
3:45 – 4:10 pm	Discussion
4:30 – 6:00 pm	Poster Session and Social
6:00 – 7:00 pm	<i>Dinner</i>
7:30 – 9:45 pm	EVENING SESSION: “Drug Resistance: Novel Strategies to Prevent or Manage” Discussion Leader: Jeff Settleman, Genentech, San Francisco, CA
7:30 – 7:45 pm	Introduction – Jeff Settleman
7:45 – 8:15 pm	Katerina Politi, Yale University, New Haven, CT "Strategies to Prevent and Overcome Resistance to EGFR-directed Therapies in Lung Cancer"
8:15 – 8:40 pm	Discussion
8:45 – 9:15 pm	Martin McMahon, University of California, San Francisco, CA “Targeting BRAF Mutated Cancers in Pre-clinical Models”
9:15 – 9:45 pm	Discussion
9:45 pm –	<i>Social</i>

TUESDAY JULY 15

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	MORNING SESSION: “Engaging T Cells as Cancer Therapy” Discussion Leader: Ira Mellman, Genentech, San Francisco, CA
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	Glen Dranoff, Dana Farber Cancer Institute, Boston, MA “Mechanisms of Protective Tumor Immunity”
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	<i>Coffee Break</i>
10:00 – 10:30 am	Jerome Galon, INSERM, Paris, FR “Immune Contexture: A Novel Paradigm for Cancer”
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	James Allison, MD Anderson Cancer Center, Houston, TX “Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities”
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
1:00 – 4:30 pm	OPEN NETWORKING AFTERNOON
4:30 – 5:45 pm	Poster Session and Social
6:00 – 7:00 pm	<i>Dinner</i>
7:30 – 9:45 pm	EVENING SESSION: “The Tumor Stroma: Target-rich Environment?” Discussion Leader: David Tuveson, Cold Spring Harbor Laboratories, NY
7:30 – 7:45 pm	Introduction
7:45 – 8:15 pm	Cyrus Ghajar, Fred Hutchinson Cancer Research Center, Seattle, WA “The Dormant Switch: Biological Insight and Therapeutic Implications”
8:15 – 8:40 pm	Discussion
8:45 – 9:15 pm	Melissa Junttila, Genentech, San Francisco, CA “Targeted Therapy Induces Stromal-mediated Drug Resistance in Melanoma”
9:15 – 9:40 pm	Discussion
9:45 pm –	<i>Social</i>

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 11:00 am	MORNING SESSION: “Revisiting the Targeting of Kras” Discussion Leader: Frank McCormick, National Cancer Institute, Bethesda, MD
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	Kevan Shokat, University of California, San Francisco, CA "Directly Targeting the Switch-II Pocket Specifically in K-Ras (G12C)"
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	<i>Coffee Break</i>
10:00 – 10:30 am	Julian Downward, Cancer Research United Kingdom "Mechanisms of Transformation by RAS Oncogenes: Searching for Novel Therapeutic Approaches"
10:30 – 10:55 am	Discussion
11:00 – 12:00 pm	ORAL PRESENTATIONS – Four Selected Presenters from the Posters
12:00 – 1:00pm	<i>Lunch</i>
2:00 – 5:20 pm	AFTERNOON SESSION: “Epigenetics” Discussion Leader: Joe Costello, University of California, San Francisco
2:00 – 2:15 pm	Introduction
2:15 – 2:45 pm	Charles Roberts, Dana Farber Cancer Institute, Boston, MA “SWI/SNF Chromatin Remodeling Complexes in Cancer”
2:45 – 3:10 pm	Discussion
3:10 – 3:40 pm	Jonathan Licht, Northwestern University, Evanston, IL “Disorders of Histone Methylation in Hematological Malignancies”
3:40 – 4:05 pm	Discussion
4:05 – 4:25 pm	<i>Coffee Break</i>
4:25 – 4:55 pm	Jolanta Grembecka, University of Michigan, Ann Arbor, MI “Therapeutic Targeting of Menin in Cancer”
4:55 – 5:20 pm	Discussion
6:00 – 10:00 pm	<i>Farewell Banquet</i>

THURSDAY JULY 17

7:00 - 8:30 am *Breakfast*

CHECK OUT BY 11:00 AM

SPONSOR ACKNOWLEDGEMENTS

This meeting would not be possible without the generous contributions from our many friends and colleagues:

AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Genentech
Janssen Pharmaceuticals
Merck
Novartis
Pfizer

MOLECULAR THERAPEUTICS OF CANCER RESEARCH CONFERENCE 2015 – SAVE THE DATE!!

TUFTS UNIVERSITY, Medford, Massachusetts
PROGRAM CHAIR: TBN
JULY 12-16, 2015